Review of solitary plasmacytoma radiotherapy outcomes in Indian tertiary care

Photo by Logan Voss / Unsplash

medRxiv Published April 18, 2026 Medically reviewed April 25, 2026 Study authors: Podder, D.; Sonowal, H.; Saha, S.; Shah, B.; Ghosh, S.; Kumar, J.; Nag, A.; Chattyopadhyay, D.; Jave… DOI ↗ By Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

Key Takeaway

Consider that this retrospective audit shows long median PFS and TTNT after radiotherapy for solitary plasmacytoma, but evidence is observational.

This is a retrospective audit review from a tertiary care center in eastern India, focusing on outcomes for 46 patients with solitary plasmacytoma treated with local radiotherapy. The authors synthesized data on median overall survival (OS), progression-free survival (PFS), and time to next treatment (TTNT).

The key findings are a median PFS of 9.22 years (95% CI: 5.8-12.6) and a median TTNT of 9.86 years (95% CI: 6.8-12.9). Median OS was not reached during the study. The median follow-up was 5.4 years (95% CI: 1.8-9.0).

The authors note that adverse events, serious adverse events, discontinuations, and tolerability were not reported. The study is limited by its retrospective, single-center design and lack of a comparator group.

Practice relevance is not specified. The observational nature of the audit means causal conclusions about radiotherapy efficacy cannot be drawn. The findings may inform local practice but require validation in prospective studies.

Study Details

Sample sizen = 46

EvidenceLevel 5

PublishedApr 2026

View Original Abstract ↓

Introduction: Solitary plasmacytomas (SP) are rare neoplasm of localised proliferation of clonal plasma cells. It can be classified based on site of involvement and bone marrow involvement. It is an indolent disease in the majority of patients. Primary modality of treatment is radiotherapy and surgical excision. Materials and methods: This was a retrospective audit of SP who were treated and followed up at a tertiary care center in eastern India from January 2012 to December 2025. Patients who has solitary plasma cytoma with more than 10% plasma cells, POEMS syndrome, have been excluded from analysis. Results: We identified 46 patients of SP. The median age of the studied population was 53 years (23-75 years). Males were more commonly affected than females (M:F=2.2:1). Most common chief complaints were bony pain (67.4%). SBP was seen in 39 (84.8%) cases whereas SEP was seen in 7 (15.2%) cases. Vertebra was the most common site of involvement (61.4%). Median M band concentration 0.24 g/dL (0.1 to 1.95 gm/dL). IgG was the most common isotype accounting for 60.6% cases. Six cases (13%) had minimal bone marrow involvement. The majority of the patients received local radiotherapy (89.1%). With a median follow up of 5.4 years (95% CI: 1.8 - 9.0), median OS was not reached, median PFS was 9.22 years (95% CI: 5.8-12.6), median time to next treatment (TTNT) was 9.86 years (95% CI: 6.8 - 12.9). Conclusion: Solitary plasmacytoma commonly affects young males. Bones are more commonly affected than extramedullary sites. SP has a lower rate of progression and excellent prognosis when treated with local radiotherapy.